fda approves first oral glp-1 obesity drug august 1 2025 for weight management FDA Approves Generic Version of

Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials

Navigating Your Rights and Legal Options After Experiencing Drug-Related Injuries Patients who suffer from drug-induced conditions like gastroparesis face a complex recovery path

FDA actively restricts the distribution of compounded GLP-1 drugs and explicitly advises against their use

doi: 10.1016/0167-4838(82)90041-3

Always work with a qualified clinician before making changes to your health protocol.

In the first study, the Authors observed that GLP-1 levels were similar in PCOS and controls in the early phase of the 75-g oral glucose tolerance test (OGTT) until 60 min, but that GLP-1 levels were significantly lower after 180 min, suggesting that women with PCOS might have reduced GLP-1 secretion in the late postprandial phase [45]